Patents by Inventor Rolf Berge
Rolf Berge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120276212Abstract: The present invention concerns a composition prepared from a combination of plant oil and/or fish oil and a compound comprising non. ?-oxidizable fatty acid analogues, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. The present invention also concerns an animal feed prepared from a combination of plant oil and/or fish oil and a compound comprising non ?-oxidizable fatty acid analogues, the use of said feed for improving the body composition of an animal, and a product produced from said animal.Type: ApplicationFiled: March 19, 2012Publication date: November 1, 2012Applicant: LIFE SCIENCE NUTRITION ASInventor: Rolf Berge
-
Patent number: 8206739Abstract: The present invention relates to the use of a enzyme treated fish protein hydrolyzate (FPH). The FPH material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. FPH also induces a favorable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A preferable embodiment of the invention relates to the use of FPH as an anti-atherogenic and cardio protective agent, either given as a pharmaceutical or as a functional food.Type: GrantFiled: July 2, 2004Date of Patent: June 26, 2012Assignee: Atlantic Garden ASInventor: Rolf Berge
-
Publication number: 20120101161Abstract: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 29, 2011Publication date: April 26, 2012Applicant: LIFE SCIENCE NUTRITION ASInventors: Rolf Berge, Pal Aukrust
-
Patent number: 8088825Abstract: The present invention relates to fatty acid analogues of the general formula R1-[xi-CH2]n—COOR2 and in particular to a method of treating inflammatory disorder selected from the group consisting of rheumatoid arthritis, systemic vasculitis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and polymyositis; comprising administering to a mammal in need thereof, an effective amount of tetradecylthioaceticacid or tetradecylselenoacetic acid; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 27, 2001Date of Patent: January 3, 2012Assignee: Life Science Nutrition ASInventors: Rolf Berge, Pal Aukrust
-
Patent number: 7902399Abstract: The present invention relates to novel fatty acid analogous of the general formula (I): R1—[xi—CH2]n—COOR2 wherein R1 is: a C6-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C6-C24 alkyne, and/or a C6-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy or C1-C4 alkyl, and wherein R2 represents hydrogen or C1-C4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, and with the proviso that if R1 is an alkye, then the carbon-carbon triple bond is positioned between the (?-1) carbon and the (?-2) carbon, or between the (?-2) carbon and the (?-3) carbon, or between the (?-3) carbon and the (?-4) carbon, aType: GrantFiled: March 2, 2001Date of Patent: March 8, 2011Assignee: Thia Medica ASInventors: Rolf Berge, Leiv K. Sydnes, Jon Songstad
-
Patent number: 7659242Abstract: The present invention concerns a composition prepared from a combination of non ?-oxidizable fatty acid entities and a protein material, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. An alternative embodiment of the invention includes oil in the composition The present invention also concerns an animal feed prepared from a combination of a protein material and a compound comprising non ?-oxidizable fatty acid analogues, the use of said feed for improving the body composition of an animal, and a product produced from said animal.Type: GrantFiled: July 19, 2005Date of Patent: February 9, 2010Assignee: Thia Medica ASInventor: Rolf Berge
-
Publication number: 20100029973Abstract: The invention comprises the use of compounds comprising non ?-oxidizable fatty acid entities according to formula (I) or (II) for the preparation of a pharmaceutical composition for the prevention and/or treatment of conditions associated with low/decreased bone mineral density (BMD), and/or for increasing the BMD by decreasing the bone resorption.Type: ApplicationFiled: July 10, 2006Publication date: February 4, 2010Inventor: Rolf Berge
-
Patent number: 7378443Abstract: A fatty acid analogue of the general formula: R1-[xi-CH2]n—COOR2, wherein R1 is: a C2-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C2-C24 alkyne, and/or a C1-C24 alkyl, or a C1-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy or C1-C4 alkyl, and wherein R2 represents hydrogen or C1-C4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, and or a salt, prodrug or complex thereof is used in the treatment and/or prevention of primary and secondary metastatic neoplasms.Type: GrantFiled: July 13, 2001Date of Patent: May 27, 2008Assignee: Thia Medica, ASInventor: Rolf Berge
-
Publication number: 20070141083Abstract: The present invention relates to the use of a single-cell protein material (SCP). The SCP material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. SCP also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A preferable embodiment of the invention relates to the use of SCP as an anti-atherogenic and cardio protective agent, either given as a pharmaceutical or as nutritional composition, e.g. as a functional food.Type: ApplicationFiled: July 2, 2004Publication date: June 21, 2007Inventors: Rolf Berge, Gunnar Kleppe
-
Publication number: 20070142274Abstract: The present invention relates to the use of a enzyme treated fish protein hydrolyzate (FPH). The FPH material lowers the concentration of cholesterol in plasma, and triglycerides in the liver. FPH also induces a favourable change in the fatty acid pattern, and lowers the concentration of homocysteine in plasma. A preferable embodiment of the invention relates to the use of FPH as an anti-atherogenic and cardio protective agent, either given as a pharmaceutical or as a functional food.Type: ApplicationFiled: July 2, 2004Publication date: June 21, 2007Inventor: Rolf Berge
-
Patent number: 7230029Abstract: The present invention relates to fatty acid analogues of the general formula (I): R1-[xi-CH2]n—COOR2 wherein R1 is; a C1–C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C1–C24 alkyne, and/or a C1–C24 alkyl, or a C1–C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1–C4 alkoxy, C2–C4 alkylthio, C1–C5 acyloxy or C1–C4 alkyl, and wherein R2 represents hydrogen or C1–C4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, and with the proviso that if R1 is an alkyne or alkene, then the carbon-carbon triple bond or double bond is positioned between the (?-1) carbon and the (?-2) carbon, or between the (?-2) carbon and the (?-3) carbon, or between tType: GrantFiled: September 27, 2001Date of Patent: June 12, 2007Assignee: Thia Medica ASInventors: Rolf Berge, Karsten Kristiansen
-
Publication number: 20070015795Abstract: The present invention concerns a composition prepared from a combination of non ?-oxidizable fatty acid entities and a protein material, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. An alternative embodiment of the invention includes oil in the composition The present invention also concerns an animal feed prepared from a combination of a protein material and a compound comprising non ?-oxidizable fatty acid analogues, the use of said feed for improving the body composition of an animal, and a product produced from said animal.Type: ApplicationFiled: July 19, 2005Publication date: January 18, 2007Inventor: Rolf Berge
-
Publication number: 20070009608Abstract: The present invention concerns a composition prepared from a combination of plant oil and/or fish oil and a compound comprising non ?-oxidizable fatty acid analogues, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes, fatty liver, hypercholesterolemia, dyslipidemia, atherosclerosis, coronary heart disease, thrombosis, stenosis, secondary stenosis, myocardial infarction, stroke, elevated blood pressure, endothelial dysfunction, procoagulant state, polycystic ovary syndrome, the metabolic syndrome, cancer, inflammatory disorders and proliferate skin disorders. The present invention also concerns an animal feed prepared from a combination of plant oil and/or fish oil and a compound comprising non ?-oxidizable fatty acid analogues, the use of said feed for improving the body composition of an animal, and a product produced from said animal.Type: ApplicationFiled: July 19, 2005Publication date: January 11, 2007Inventor: Rolf Berge
-
Publication number: 20060105987Abstract: The present invention provides a lipid compound comprising at least one non-polar moiety and a polar moiety, wherein each or at least one non-polar moiety is of the formula X—Y-Z-, wherein X is a hydrocarbyl chain, Y is selected from at least one of S, Se, SO2, SO, and O, and Z is an optional hydrocarbyl group, wherein the polar moiety is of the formula —[C(O)]mPHG, wherein PHG is a polar head group, and wherein m is the number of non-polar moieties.Type: ApplicationFiled: June 16, 2003Publication date: May 18, 2006Inventors: Andrew Miller, Michael Jorgensen, Rolf Berge, Jon Skorve
-
Patent number: 7026356Abstract: The present invention relates to novel fatty acid analogues of the general formula (I): CH3—[CH2]m—[xi—CH2]n—COOR, wherein n is an integer from 1 to 12, and wherein m is an integer from 0 to 23, and wherein i is an odd number which indicates the position relative to COOR, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and wherein R represents hydrogen or C1–C4 alkyl, with the proviso that at least one of the Xi is not CH2, or a salt, prodrug or complex thereof, for the preparation of a pharmaceutical composition for the treatment and/or prevention of primary and/or secondary stenosis. Further the present invention relates to the use of said compounds for the prevention and/or treatment of a disease caused by procedural vascular trauma and/or pathological proliferation of smooth muscle cells, and/or an increased level of plasma homocysteine.Type: GrantFiled: May 17, 2002Date of Patent: April 11, 2006Inventor: Rolf Berge
-
Publication number: 20050165103Abstract: The present invention relates to fatty acid analogues of the general formula I: R1-[xi-CH2]n—COOR2; wherein R1 is; a C1-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or, a C1-C24 alkyne, and/or, a C1-C424 alkyl, or a C1-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy or C1-C4 alkyl, and; wherein R2 represents hydrogen or C1-C4 alkyl, and; wherein n is an integer from 1 to 12, and; wherein i is an old number and indicates the position relative to COOR2, and; wherein Xi independent of each other are selected from the group comprising, O, S, SO, SO2, Se and CH2, and; with the proviso that at least one of the Xi is not CH2; which can be used for the treatment and/or prevention of inflammatory disorders.Type: ApplicationFiled: November 27, 2001Publication date: July 28, 2005Inventors: Rolf Berge, Pal Aukrust
-
Publication number: 20040213442Abstract: The present invention relates to novel fatty acid analogous of the general formula (I): R1—[xi—CH2]n—COOR2 wherein R1 is: a C6-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C6-C24 alkyne, and/or a C6-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy.Type: ApplicationFiled: November 12, 2002Publication date: October 28, 2004Inventors: Rolf Berge, Leiv K Sydnes, Jon Songstad
-
Publication number: 20040024063Abstract: The present invention relates to fatty acid analogues of general formula (I): R1-[xi-CH2]n—COOR2, wherein is: a C1-C24 alkene with one or more double bonds and/or with one or more triple bonds; and/or a C1-C24 alkyne, and/or a C1-C24 alkyl, or an alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C1-C4 alkylthio, C2-C5 acyloxy or C1-C4 alkyl, and wherein R2 represents hydrogen or C1-C4 alkyl, and wherein is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, which can be used for the treatment and/or prevention of primary and secondary metastatic neoplasms.Type: ApplicationFiled: January 2, 2003Publication date: February 5, 2004Inventor: Rolf Berge
-
Publication number: 20040019108Abstract: The present invention relates to fatty acid analogues of the general formula (I): R1-[xi-CH2]n—COOR2 wherein R1 is; a C1-C24 alkene with one or more double bonds and/or with one or more triple bonds, and/or a C1-C24 alkyne, and/or a C1-C24 alkyl, or a C1-C24 alkyl substituted in one or several positions with one or more compounds selected from the group comprising fluoride, chloride, hydroxy, C1-C4 alkoxy, C2-C4 alkylthio, C1-C5 acyloxy or C1-C4 alkyl, and wherein R2 represents hydrogen or C1-C4 alkyl, and wherein n is an integer from 1 to 12, and wherein i is an odd number and indicates the position relative to COOR2, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and with the proviso that at least one of the Xi is not CH2, and with the proviso that if R1 is an alkyne or alkene, then the carbon-carbon triple bond or double bond is positioned between the (&ohgr;-1) carbon and the (&ohgr;-2) carbon, or between the (&ohgr;-2) carbon andType: ApplicationFiled: May 8, 2003Publication date: January 29, 2004Inventors: Rolf Berge, Karsten Kristiansen
-
Publication number: 20020198259Abstract: The present invention relates to novel fatty acid analogues of the general formula (I): CH3—[CH2]m—[xi—CH2]n—COOR, wherein n is an integer from 1 to 12, and wherein m is an integer from 0 to 23, and wherein i is an odd number which indicates the position relative to COOR, and wherein Xi independent of each other are selected from the group comprising O, S, SO, SO2, Se and CH2, and wherein R represents hydrogen or C1-C4 alkl, with the proviso that at least one of the Xi is not CH2, or a salt, prodrug or complex thereof, for the preparation of a pharmaceutical composition for the treatment and/or prevention of primary and/or secondary stenosis. Further the present invention relates to the use of said compounds for the prevention and/or treatment of a disease caused by procedural vascular trauma and/or pathological proliferation of smooth muscle cells, and/or an increased level of plasma homocysteine.Type: ApplicationFiled: May 17, 2002Publication date: December 26, 2002Inventor: Rolf Berge